Company News
As Sir Noddy of Holder once said: “It’s Chriiiistmaaaas!” Oh, you’ve noticed. While some retailers may have been trying to […]
Dec 02nd, 2022
American drug giant Merck is reportedly eying up a possible acquisition of the biopharmaceuticals company Cubist Pharmaceuticals.
The deal, according to the New York Times, could be announced as early as next week. Merck could pay around $100 a share in a move which would value the US antibiotics maker in the range of $7.5 billion.
Cubist, which makes drugs to treat dangerous bacteria and superbugs in the developing world, has seen its share value nearly double over the last two years.
Should the deal go through it would mark the latest in a long line of multibillion-dollar pharmaceutical mergers and acquisitions.
Merck, one of America’s largest makers of vaccines, prescription products and oncology treatments, has a market value in excess of $174 billion.